Hofseth BioCare ASA (HOFBF)
USD 0.16
(0.0%)
USD 0.16
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 29.87 Million NOK | 816.39% |
| 2022 | -6.16 Million NOK | 11.74% |
| 2021 | -6.98 Million NOK | -11.9% |
| 2020 | -6.24 Million NOK | -42.18% |
| 2019 | -4.39 Million NOK | -400.44% |
| 2018 | 1.46 Million NOK | -62.58% |
| 2017 | 3.9 Million NOK | 104.66% |
| 2016 | -83.83 Million NOK | -129.23% |
| 2015 | -36.57 Million NOK | -810.16% |
| 2014 | 5.15 Million NOK | -83.9% |
| 2013 | 31.98 Million NOK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 303.1 Thousand USD | 2570.84% |
| 2024 Q1 | -122.61 Thousand USD | 95.65% |
| 2023 Q3 | -817.79 Thousand USD | -407.38% |
| 2023 FY | 44.18 Million USD | 816.39% |
| 2023 Q1 | -1.82 Million USD | 7.51% |
| 2023 Q2 | 266.05 Thousand USD | 114.57% |
| 2023 Q4 | -2.99 Million USD | -266.48% |
| 2022 Q3 | -1.56 Million NOK | -52.35% |
| 2022 Q2 | -1.02 Million NOK | 31.25% |
| 2022 FY | -6.16 Million NOK | 11.74% |
| 2022 Q1 | -1.49 Million NOK | 33.41% |
| 2022 Q4 | -1.97 Million NOK | -26.29% |
| 2021 Q4 | -2.24 Million NOK | -11.75% |
| 2021 Q3 | -2 Million NOK | -163.94% |
| 2021 FY | -6.98 Million NOK | -11.9% |
| 2021 Q1 | -1.12 Million NOK | -117.62% |
| 2021 Q2 | -760.12 Thousand NOK | 32.39% |
| 2020 Q4 | 6.37 Million NOK | 86.74% |
| 2020 Q1 | 12.28 Million NOK | 325.82% |
| 2020 FY | -6.24 Million NOK | -42.18% |
| 2020 Q2 | 7.64 Million NOK | -37.74% |
| 2020 Q3 | 3.41 Million NOK | -55.32% |
| 2019 Q4 | -5.43 Million NOK | -240.66% |
| 2019 FY | -4.39 Million NOK | -400.44% |
| 2019 Q3 | 3.86 Million NOK | -35.74% |
| 2019 Q2 | 6.01 Million NOK | 59.83% |
| 2019 Q1 | 3.76 Million NOK | -17.29% |
| 2018 Q3 | 2.57 Million NOK | -7.75% |
| 2018 Q2 | 2.78 Million NOK | 12.83% |
| 2018 Q1 | 2.47 Million NOK | -62.61% |
| 2018 FY | 1.46 Million NOK | -62.58% |
| 2018 Q4 | 4.55 Million NOK | 77.01% |
| 2017 FY | 3.9 Million NOK | 104.66% |
| 2017 Q3 | 6.95 Million NOK | 1155.42% |
| 2017 Q1 | 49.43 Million NOK | 1062.14% |
| 2017 Q2 | 554 Thousand NOK | -98.88% |
| 2017 Q4 | 6.6 Million NOK | -5.02% |
| 2016 Q4 | -5.13 Million NOK | 84.6% |
| 2016 Q2 | -35.16 Million NOK | -366.85% |
| 2016 Q1 | -7.53 Million NOK | -219.42% |
| 2016 FY | -83.83 Million NOK | -129.23% |
| 2016 Q3 | -33.37 Million NOK | 5.09% |
| 2015 Q4 | -2.35 Million NOK | -568.79% |
| 2015 Q2 | -3.7 Million NOK | 20.88% |
| 2015 Q1 | -4.68 Million NOK | 54.2% |
| 2015 FY | -36.57 Million NOK | -810.16% |
| 2015 Q3 | 503 Thousand NOK | 113.58% |
| 2014 Q1 | 3.98 Million NOK | -69.16% |
| 2014 Q4 | -10.21 Million NOK | -386.62% |
| 2014 Q3 | 3.56 Million NOK | 2.59% |
| 2014 Q2 | 3.47 Million NOK | -12.86% |
| 2014 FY | 5.15 Million NOK | -83.9% |
| 2013 Q4 | 12.93 Million NOK | -12.68% |
| 2013 Q1 | -3.72 Million NOK | -49.42% |
| 2013 Q2 | 4.98 Million NOK | 233.81% |
| 2013 FY | 31.98 Million NOK | 0.0% |
| 2013 Q3 | 14.8 Million NOK | 196.91% |
| 2012 Q3 | 2.75 Million NOK | 5.04% |
| 2012 Q2 | 2.61 Million NOK | 720.38% |
| 2012 Q4 | -2.49 Million NOK | -190.7% |
| 2012 Q1 | -422 Thousand NOK | -168.2% |
| 2011 Q3 | -136 Thousand NOK | 30.61% |
| 2011 Q2 | -196 Thousand NOK | -145.18% |
| 2011 Q1 | 433.8 Thousand NOK | 389.06% |
| 2011 Q4 | 618.8 Thousand NOK | 555.0% |
| 2010 Q4 | 88.7 Thousand NOK | -20.52% |
| 2010 Q3 | 111.6 Thousand NOK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 11.7 Million USD | -155.228% |
| Arch Therapeutics, Inc. | -2439.00 USD | 1225069.25% |
| CSL Limited | 7.56 Billion USD | 99.605% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 74.916% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -16821.726% |
| BioStem Technologies, Inc. | 15.42 Million USD | -93.694% |
| Capstone Therapeutics Corp. | 9.61 Million USD | -210.863% |
| Qrons Inc. | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 9450.969% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 215.811% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -42581.429% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 24145.682% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 62009.696% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -21164.769% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 92.705% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | -99.193% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -963052.805% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | -205.054% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -45355.514% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 87587.555% |
| Mesoblast Limited | -35.16 Million USD | 184.955% |
| Marizyme, Inc. | 457.7 Thousand USD | -6427.61% |
| Genus plc | 178.7 Million USD | 83.281% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 86.426% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -47913.692% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -7184.142% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 271709.091% |
| ContraFect Corporation | -154 Thousand USD | 19500.649% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 59854.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -38822.109% |
| IMV Inc. | -962.29 Thousand USD | 3204.755% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 7810.174% |
| MultiCell Technologies, Inc. | 49.32 USD | -60577758.881% |
| ONE Bio Corp. | 20.12 Million USD | -48.454% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 25.799% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -60998.16% |
| Q BioMed Inc. | -8988.00 USD | 332509.88% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | -5.741% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 193804.616% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 32.645% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 2717.181% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 603431.987% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 30738.363% |
| GB Sciences, Inc. | -624.00 USD | 4788080.769% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 34829.39% |
| HST Global, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 14364042.308% |
| Enzolytics Inc. | 30.7 Thousand USD | -97193.865% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -6092.984% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 97.305% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 5906.884% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -4739.29% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 337464.499% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 35731.91% |
| Kadimastem Ltd | -630.13 Thousand USD | 4841.342% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -2924.046% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 252546.134% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -16821.726% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | -2101.463% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 103124.138% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -6538.699% |
| SYBLEU INC | 11.69 Thousand USD | -255346.306% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | -548.372% |
| Bioxytran, Inc. | -8285.00 USD | 360715.57% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 8109.92% |
| Neutra Corp. | 14.33 Thousand USD | -208319.951% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 36535.366% |
| PureTech Health plc | -1.6 Million USD | 1963.818% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 3084.012% |
| IXICO plc | 3.27 Million USD | -813.67% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 4405.043% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 1768.174% |
| CSL Limited | 7.7 Billion USD | 99.612% |
| Cellectis S.A. | 18 Thousand USD | -165883.333% |